Nature Medicine· Lixin Guo·· 4 天前AI 评分60
口服小分子GLP-1RA safiglipron对比达格列净治疗2型糖尿病的III期试验
Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial
AI 导读
Safiglipron与dapagliflozin（达格列净）头对头III期随机双盲试验显示，每日一次口服safiglipron在所有测试剂量下降低HbA1c均不劣于达格列净，90mg剂量下更优。两药减重幅度相近，safiglipron血糖控制改善更明显，安全性可接受。
来源：Nature Medicine · nature.com